Pfizer Discontinues Phase 3 Trial of Sutent® in Metastatic Colorectal Cancer

NEW YORK--(BUSINESS WIRE)--Jun 30, 2009 - Pfizer Inc announced today the discontinuation of the SUN 1122 Phase 3 trial that evaluated Sutent® (sunitinib malate) plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and leucovorin) versus...


Comments

Comments are closed.